VRTX

Vertex Pharmaceuticals Incorporated Press Releases

$99.07
*  
1.25
1.28%
Get VRTX Alerts
*Delayed - data as of Jul. 11, 2014  -  Find a broker to begin trading VRTX now
Exchange: NASDAQ
Industry: Health Care
Community Rating:
 
 
Symbol List Views
FlashQuotes InfoQuotes
Stock Details
Summary Quote Real-Time Quote After Hours Quote Pre-market Quote Historical Quote Option Chain
CHARTS
Basic Chart Interactive Chart
COMPANY NEWS
Company Headlines Press Releases Market Stream
STOCK ANALYSIS
Analyst Research Guru Analysis Stock Report Competitors Stock Consultant Stock Comparison
FUNDAMENTALS
Call Transcripts Annual Report Income Statement Revenue/EPS SEC Filings Short Interest Dividend History
HOLDINGS
Ownership Summary Institutional Holdings Insiders
(SEC Form 4)
 Save stocks for next time
Viewing
Filtered By
Ordered By

Vertex Announces Retirement of Peter Mueller, Ph.D.
7/10/2014 8:00:00 AM - Business Wire

Vertex Submits Supplemental New Drug Application (sNDA) to U.S. Food and Drug Administration for Use of KALYDECO® (ivacaftor) in People 18 and Older with Cystic Fibrosis who have the R117H Mutation
6/30/2014 4:05:00 PM - Business Wire

Faruqi & Faruqi, LLP Encourages Investors Who Suffered Losses In Excess Of $100,000 Investing In Vertex Pharmaceuticals Inc. To Contact The Firm
6/27/2014 10:17:00 PM - PR Newswire

Vertex Receives European CHMP Positive Opinion for KALYDECO™ (ivacaftor) in Eight Non-G551D Gating Mutations
6/27/2014 7:14:00 AM - Business Wire

Biotech Stocks on the Move -- Research on CTI BioPharma, BioMarin Pharma, Vertex Pharma, and Northwest Biotherapeutics
6/27/2014 7:00:00 AM - PR Newswire

Two 24-Week Phase 3 Studies of Lumacaftor in Combination with Ivacaftor Met Primary Endpoint with Statistically Significant Improvements in Lung Function (FEV1) in People with Cystic Fibrosis who have Two Copies of the F508del Mutation
6/24/2014 7:00:00 AM - Business Wire

Vertex Licenses VX-787 to Janssen Pharmaceuticals for the Treatment of Influenza
6/18/2014 8:30:00 AM - Business Wire

Vertex Announces a Signed Letter of Intent to Enable Public Reimbursement of KALYDECO® (ivacaftor) in Canada for Eligible People with Cystic Fibrosis
6/16/2014 5:15:00 PM - Business Wire

Kirby McInerney LLP Reminds Investors of the Lead Plaintiff Deadline in the Class Action Lawsuit Against Vertex Pharmaceuticals, Inc.
6/12/2014 12:12:00 PM - Business Wire

Vertex Announces Presentation of New KALYDECO™ (ivacaftor) Data at European Cystic Fibrosis Society Conference
6/12/2014 9:00:00 AM - Business Wire

Proof-of-Concept Study of Ivacaftor Monotherapy Showed Improvements in Lung Function After Two Weeks of Treatment in People with Cystic Fibrosis who have a Residual Function Mutation
6/4/2014 8:00:00 AM - Business Wire

Vertex to Present at the Goldman Sachs Global Healthcare Conference on June 10
6/3/2014 4:01:00 PM - Business Wire

SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Vertex Pharmaceuticals Incorporated - VRTX
6/3/2014 3:24:00 PM - PR Newswire

Faruqi & Faruqi, LLP Encourages Investors Who Suffered Losses in Excess of $100,000 Investing in Vertex Pharmaceuticals Inc. to Contact the Firm
5/30/2014 9:48:00 PM - Market Wire

Milberg LLP Announces Filing of a Class Action Lawsuit against Vertex Pharmaceuticals
5/30/2014 1:02:00 PM - PR Newswire

Vertex to Present at the UBS Global Healthcare Conference on May 20
5/13/2014 4:01:00 PM - Business Wire

William Young Joins Vertex Board of Directors
5/7/2014 4:05:00 PM - Business Wire

Addition of VX-661 to KALYDECO® (ivacaftor) Improves Lung Function in People with CF Who Are Heterozygous for the F508del and G551D Mutations in 28-day Phase 2 Proof-of-Concept Study
5/1/2014 4:02:00 PM - Business Wire

Vertex Reports First Quarter 2014 Financial Results and Provides Updates on Key Business Priorities
5/1/2014 4:01:00 PM - Business Wire

Analysts View on Biotech Equities -- Research on Organovo Holdings, BioMarin Pharma, Vertex Pharma, and Spectrum Pharma
4/15/2014 11:15:00 AM - PR Newswire